Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash & Equivalents: 2011-2024

Historic Cash & Equivalents for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $779.7 million.

  • Ptc Therapeutics' Cash & Equivalents rose 27.87% to $672.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $672.6 million, marking a year-over-year increase of 27.87%. This contributed to the annual value of $779.7 million for FY2024, which is 31.26% up from last year.
  • Ptc Therapeutics' Cash & Equivalents amounted to $779.7 million in FY2024, which was up 31.26% from $594.0 million recorded in FY2023.
  • Ptc Therapeutics' Cash & Equivalents' 5-year high stood at $779.7 million during FY2024, with a 5-year trough of $189.7 million in FY2021.
  • For the 3-year period, Ptc Therapeutics' Cash & Equivalents averaged around $551.2 million, with its median value being $594.0 million (2023).
  • As far as peak fluctuations go, Ptc Therapeutics' Cash & Equivalents declined by 27.50% in 2020, and later skyrocketed by 112.27% in 2023.
  • Yearly analysis of 5 years shows Ptc Therapeutics' Cash & Equivalents stood at $208.8 million in 2020, then fell by 9.14% to $189.7 million in 2021, then surged by 47.50% to $279.8 million in 2022, then surged by 112.27% to $594.0 million in 2023, then surged by 31.26% to $779.7 million in 2024.